Background

After qualifying as a microbiologist with a special interest in herbs, botany and plant pathology, Patricia worked in microbiology, vaccines and human immunology at laboratories in Australia, the United Kingsdom and USA. She specialised in immunology research developing new drugs to treat organ transplant rejection, chronic inflammation and autoimmune diseases (diabetes and rheumatoid arthritis).

A Doctor of Philosophy (PhD) in Medical Biology from the University of Melbourne, Patricia has taught medicinal and biomedical science students at both Melbourne and Monash Universities. Currently her focus is project management including the collation and archiving of clinical and experimental data.

In addition to her scientific work Patricia teaches yoga, is a Reiki Master/teacher, a qualified practitioner of Western herbal medicine, and an Ayurvedic therapist. While she has great respect for and knowledge of Western science and medicine Patricia also believes that a more holistic approach to health will bring added benefits, and make Western medicine even more effective.

Appointments

• 2007-present: Senior Research Fellow & Research Project Manager, Burnet Institute for Medical Research, Melbourne, Victoria, Australia
• 2006-present: Honorary Senior Lecturer, Department of Immunology, Monash University, Victoria, Australia
• 2001-present: Honorary Senior Research Fellow, Department of Pathology, University of Melbourne, Victoria, Australia
• 2001-2006: Senior Research Fellow & Research Project Manager, Austin Research Institute, Austin Hospital, Victoria, Australia
• 1999-2000: National Heart Foundation Senior Research Fellow, Department of Surgery, University of Melbourne, Australia
• 1989-98: Lecturer/Research Fellow, Department of Surgery, University of Melbourne, Australia
• 1995-96: Postdoctoral Research Fellow, Cardiovascular Research Laboratory, Harvard School of Public Health, Harvard University, Boston, USA
• 1983-88: Senior Technical Officer and Postdoctoral Fellow, Department of Surgery, University of Melbourne, Australia
• 1977-82: Graduate Research Assistant and PhD student, Walter and Eliza Hall Institute for Medical Research, Victoria, Australia
• 1975-76: Graduate Research Assistant, Nuffield Department of Surgery, Oxford University, United Kingdom

Qualifications

• 2010: Graduate Diploma of Health Science (Herbal Medicine), University of New England, Armidale, NSW, Australia
• 2000: Postgraduate Diploma of Education, University of Melbourne, Victoria, Australia
• 2000: Project Management Course, Royal Melbourne Institute of Technology, Victoria, Australia
• 1985: Doctor of Philosophy (Medical Biology/Immunology), University of Melbourne, Australia
• 1975: BASc (Biology), Royal Melbourne Institute of Technology, Australia

Awards

• 2003: Nancy Prendergast Fellowship
• 2000: TSANZ Senior Investigators Award
• 1999: TSANZ Senior Investigators Award
• 1998: National Heart Foundation Fellowship
• 1995-1996: University of Melbourne Special Studies Project Award
• 1995: Janssen-Cilag Travelling Fellowship of the TSANZ
• 1994: National Heart Foundation Travel Award
• 1992: National Heart Foundation Travel Award
• 1991: TSANZ Young Investigators Award
• 1990: International Transplantation Society Travel Award
• 1989: TSANZ President’s Prize

Publications (26)

2012 (1)

• A history of experimental small animal transplants in Australia (Book Chapter)
  Mottram PL, McKenzie IFC, McKenzie JL
  More than a footnote - The story of organ transplantation in Australia and New Zealand (Ed. Brian D Tait) . 2012 Jul

2010 (1)

• Transgenic mice expressing human FcgammaRIIa have enhanced sensitivity to induced autoimmune arthritis as well as elevated Th17 cells.
  Van de Velde NC, Mottram PL, Powell MS, Lim B, Holmdahl R, Hogarth PM
  Immunol Lett. 2010 May; 130(1-2):82-88

2009 (1)

• Inhibition of destructive autoimmune arthritis in FcgammaRIIa transgenic mice by small chemical entities.
  Pietersz GA, Mottram PL, de Velde NCV, Sardjono CT, Esparon S, Ramsland PA, Moloney G, Baell JB, McCarthy TD, Matthews BR, Powell MS, Hogarth PM
  Immunol Cell Biol. 2009 Jan; 87(1):3-12

2008 (1)

• The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement.
  Caminschi I, Proietto AI, Ahmet F, Kitsoulis S, Teh JS, Lo JCY, Rizzitelli A, Wu L, Vremec D, van Dommelen SLH, Campbell IK, Maraskovsky E, Braley H, Davey GM, Mottram P, De Velde NV, Jensen K, Lew AM, Wright MD, Heath WR, Shortman K, Lahoud MH
  Blood. 2008 Oct; 112(8):3264-3273

2007 (1)

• Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus.
  Mottram PL, Leong D, Crimeen-Irwin B, Gloster S, Xiang SD, Meanger J, Ghildyal R, Vardaxis N, Plebanski M
  Mol Pharm. 2007 Jan; 4(1):73-84

2006 (4)

• FcgammaRII and multi-system autoimmune disease.
  van de Velde NC, Mottram PL, Hogarth PM
  Springer Semin Immunopathol. 2006 Dec; 28(4):329-338
• Pathogen recognition and development of particulate vaccines: does size matter?
  Xiang SD, Scholzen A, Minigo G, David C, Apostolopoulos V, Mottram PL, Plebanski M
  Methods. 2006 Sep; 40(1):1-9
• Methods for nano-particle based vaccine formulation and evaluation of their immunogenicity.
  Kalkanidis M, Pietersz GA, Xiang SD, Mottram PL, Crimeen-Irwin B, Ardipradja K, Plebanski M
  Methods. 2006 Sep; 40(1):20-29
• Systemic immune responses in sheep, induced by a novel nano-bead adjuvant.
  Scheerlinck JP, Gloster S, Gamvrellis A, Mottram PL, Plebanski M
  Vaccine. 2006 Feb; 24(8):1124-1131

2005 (3)

• Failure of immune homeostasis -- the consequences of under and over reactivity.
  Crimeen-Irwin B, Scalzo K, Gloster S, Mottram PL, Plebanski M
  Curr Drug Targets Immune Endocr Metabol Disord. 2005 Dec; 5(4):413-422
• Development of spontaneous multisystem autoimmune disease and hypersensitivity to antibody-induced inflammation in Fcgamma receptor IIa-transgenic mice.
  Tan Sardjono C, Mottram PL, van de Velde NC, Powell MS, Power D, Slocombe RF, Wicks IP, Campbell IK, McKenzie SE, Brooks M, Stevenson AW, Hogarth PM
  Arthritis Rheum. 2005 Oct; 52(10):3220-3229
• Antigen delivery via two molecules on the CD8- dendritic cell subset induces humoral immunity in the absence of conventional "danger".
  Corbett AJ, Caminschi I, McKenzie BS, Brady JL, Wright MD, Mottram PL, Hogarth PM, Hodder AN, Zhan YF, Tarlinton DM, Shortman K, Lew AM
  Eur J Immunol. 2005 Oct; 35(10):2815-2825

2004 (3)

• Short peptide sequences containing MHC class I and/or class II epitopes linked to nano-beads induce strong immunity and inhibition of growth of antigen-specific tumour challenge in mice.
  Fifis T, Mottram P, Bogdanoska V, Hanley J, Plebanski M
  Vaccine. 2004 Nov; 23(2):258-266
• Vaccines that facilitate antigen entry into dendritic cells.
  Gamvrellis A, Leong D, Hanley JC, Xiang SD, Mottram P, Plebanski M
  Immunol Cell Biol. 2004 Oct; 82(5):506-516
• Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors.
  Fifis T, Gamvrellis A, Crimeen-Irwin B, Pietersz GA, Li J, Mottram PL, McKenzie IF, Plebanski M
  J Immunol. 2004 Sep; 173(5):3148-3154

2003 (3)

• The role of FcgammaRIIa as an inflammatory mediator in rheumatoid arthritis and systemic lupus erythematosus.
  Tan Sardjono C, Mottram PL, Hogarth PM
  Immunol Cell Biol. 2003 Oct; 81(5):374-381
• Past, present and future drug treatment for rheumatoid arthritis and systemic lupus erythematosus.
  Mottram PL
  Immunol Cell Biol. 2003 Oct; 81(5):350-353
• Unique monoclonal antibodies define expression of Fc gamma RI on macrophages and mast cell lines and demonstrate heterogeneity among subcutaneous and other dendritic cells.
  Tan PS, Gavin AL, Barnes N, Sears DW, Vremec D, Shortman K, Amigorena S, Mottram PL, Hogarth PM
  J Immunol. 2003 Mar; 170(5):2549-2556

2002 (2)

• Remission and pancreas isograft survival in recent onset diabetic NOD mice after treatment with low-dose anti-CD3 monoclonal antibodies.
  Mottram PL, Murray-Segal LJ, Han W, Maguire J, Stein-Oakley AN
  Transpl Immunol. 2002 Jun; 10(1):63-72
• FcgammaRI-deficient mice show multiple alterations to inflammatory and immune responses.
  Barnes N, Gavin AL, Tan PS, Mottram P, Koentgen F, Hogarth PM
  Immunity. 2002 Mar; 16(3):379-389

1997 (1)

• Idarubicin-anti-CD3: a new immunoconjugate that induces alloantigen-specific tolerance in mice.
  Mottram PL, Han WR, Murray-Segal LJ, Mandel TE, Pietersz GA, McKenzie IF
  Transplantation. 1997 Sep; 64(5):684-690

1996 (1)

• Engineering of recombinant soluble CD46: an inhibitor of complement activation.
  Christiansen D, Milland J, Thorley BR, McKenzie IF, Mottram PL, Purcell LJ, Loveland BE
  Immunology. 1996 Mar; 87(3):348-354

1995 (2)

• Infiltrating cells in mouse cardiac allografts after anti-CD4 monoclonal antibody treatment.
  Han WR, Mottram PL, Purcell LJ, Plenter RJ, McKenzie IF
  Transplant Proc. 1995 Jun; 27(3):2163
• Increased expression of IL-4 and IL-10 and decreased expression of IL-2 and interferon-gamma in long-surviving mouse heart allografts after brief CD4-monoclonal antibody therapy.
  Mottram PL, Han WR, Purcell LJ, McKenzie IF, Hancock WW
  Transplantation. 1995 Feb; 59(4):559-565

1993 (2)

• Comparison of CD4 depleting and nondepleting monoclonal antibodies in the mouse heart allograft model.
  Han WR, Mottram PL, McKenzie IF
  Transplant Proc. 1993 Oct; 25(5):2933-2934
• Prolonged survival of mouse cardiac allografts after CD4 or CD8 monoclonal antibody therapy is associated with selective intragraft cytokine protein expression: interleukin (IL)-4 and IL-10 but not IL-2 or interferon-gamma.
  Hancock W, Mottram PL, Purcell LJ, Han WR, Pietersz GA, McKenzie IF
  Transplant Proc. 1993 Oct; 25(5):2937-2938